enGene Therapeutics Inc. (ENGN) Q1 2026 Annual Earnings
ENGN·Reported March 9, 2026·Before market open
Diluted EPS came in at $-0.44 (+8.3% YoY), beat the $-0.55 consensus by $0.11.
Diluted EPS
$-0.44beat by $0.11
Consensus: $-0.55
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about enGene Therapeutics Inc. 's Q1 2026 earnings report.
enGene Therapeutics Inc. (ENGN) reported Q1 2026 earnings on March 9, 2026 before market open.
enGene Therapeutics Inc. reported diluted EPS of $-0.44 for Q1 2026.
EPS beat the consensus estimate of $-0.55 by $0.11.
Compared to the same quarter a year prior, diluted EPS grew 8.3% from $-0.48.
You can read the 8-K earnings release (0001193125-26-097534) and the 10-K/A periodic report (0001193125-26-059409) directly on SEC EDGAR. The filing index links above go to sec.gov.